GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00833963
- Locations
- 🇺🇸
Kendle International, Inc, Wilmington, North Carolina, United States
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Completed
- Conditions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT00813748
- Locations
- 🇺🇸
Investigational Site, San Antonio, Texas, United States
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00808210
- Locations
- 🇺🇸
Ohio State Univ Med Center, Columbus, Ohio, United States
🇺🇸Ctr for Inflammatory Disease, Nashville, Tennessee, United States
🇺🇸Phillip A Waller MD, PA, Houston, Texas, United States
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT00781612
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comp Cancer Centers of Nevada, Los Angeles, California, United States
A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00781443
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00777764
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1
Suspended
- Conditions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00753480
- Locations
- 🇺🇸
Investigational Site, Nashville, Tennessee, United States
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00747734
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00739661
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00736775
© Copyright 2024. All Rights Reserved by MedPath